- New addition to LISA TRACKER, the market’s most complete range of biotherapy monitoring kits
- New test in the field of auto-immune and inflammatory diseases
Croissy-Beaubourg and Montpellier, March 25, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that it has obtained CE marking for its monitoring test of Stelara® (ustekinumab), the 10th biotherapy monitoring test of Theradiag’s LISA TRACKER range.
Stelara® is fully human monoclonal antibody that targets the cytokines (interleukin) IL-12 and IL-23 proteins. It was approved for use in moderate to severe plaque psoriasis and psoriatic arthritis. Psoriasis is a very common autoimmune disease, affecting two-to-three percent of the world’s population[1]. Ustekinumab is also currently undergoing clinical trial[2] for the treatment of Crohn’s Disease. Sales of Stelara® were $1.3 billion in 2014.
“Theradiag is the only company in the world to offer such a large range of monitoring tests for the treatment of autoimmune and inflammatory diseases. To maintain our leadership on the market, we will develop monitoring kits for all available and future biotherapies in the fields of autoimmune diseases and cancer. The CE marking that we announce today, the 10th in our LISA TRACKER range, is a proof of this commitment” concludes Michel Finance, Chief Executive Officer of Theradiag.
About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer and HIV/AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Theradiag Investor Relations Nathalie Trepo +33 1 64 62 10 12
| NewCap Financial communications/ investor relations Valentine Brouchot/ Pierre Laurent +33 1 44 71 94 94
| Alize RP Press Caroline Carmagnol +33 6 64 18 99 59 |